Urpo
Lamminmäki
Professor, Biotechnology
InFLAMES Flagship
PhD
Areas of expertise
Antibody engineering
Bioaffinity assays
in vitro diagnostics
Teaching
Methods and application of molecular biotechnology
Antibody and protein engineering techniques
Protein chemistry
Diagnostics
Research
My research is largely focused to recombinant antibodies and other bioaffinity molecules. I am interested in developing techniques used for tailoring such molecules as well as applications of these molecules in various fields including diagnostics, drug development and biomarker discovery.
Publications
Developing and validating anti-ADA2 single-chain antibodies coupled to alkaline phosphatase for diagnosing pleural tuberculosis (2025)
Frontiers in immunology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Plasma CHI3L1 associates with brain volume loss and glial activation in multiple sclerosis (2025)
Journal of Neurology, Neurosurgery and Psychiatry
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
High‐Sensitivity Detection of Urinary Extracellular Vesicles With Upconverting Nanoparticle‐Based Lateral Flow Immunoassay (2025)
Journal of Extracellular Biology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance (2025)
Signal Transduction and Targeted Therapy
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Epitope-specific antibody fragments block aggregation of AGelD187N, an aberrant peptide in gelsolin amyloidosis (2024)
Journal of Biological Chemistry
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Fully human monoclonal antibody targeting the cysteine-rich substrate-interacting region of ADAM17 on cancer cells (2024)
Biomedicine and Pharmacotherapy
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Increased stable integration efficiency in CHO cells through enhanced nuclear localization of Bxb1 serine integrase (2024)
BMC Biotechnology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Tetraspanin immunoassay for the detection of extracellular vesicles and renal cell carcinoma (2024)
Nano select
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Plasma CHI3L1 associates with increased TSPO-PET measurable microglial activation in patients with progressive multiple sclerosis (2024)
Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Multiple Sclerosis
(Konferenssiposteri)
Controlled labelling of tracer antibodies for time-resolved fluorescence-based immunoassays (2024)
Scientific Reports
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )